Johnson & Johnson (JNJ)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of May 19, 2025

$152.49

P/E Ratio

16.95

Market Cap

$366.9B

Description
Add to research
View more

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Metrics
Add to research
View more

Overview

  • HQNew Brunswick, NJ
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerJNJ
  • Price$152.49+0.77%

Trading Information

  • Market cap$366.90B
  • Float99.86%
  • Average Daily Volume (1m)8,048,455
  • Average Daily Volume (3m)9,722,510
  • EPS$9.06

Company

  • Revenue$89.33B
  • Rev growth (1yr)2.39%
  • Net income$11.00B
  • Gross margin66.84%
  • EBITDA margin36.85%
  • EBITDA$8.07B
  • EV$410.27B
  • EV/Revenue4.59
  • P/E16.95
  • P/S4.14
  • P/B4.70
  • Debt/Equity66.90
Documents
Add to research
View more
SEC Filings
8-K (2025-04-30)
8-K (2025-04-15)
8-K (2025-04-03)
8-K (2025-02-26)
8-K (2025-02-20)
8-K (2025-01-22)
8-K (2024-10-15)
8-K (2024-09-20)
8-K (2024-09-10)
8-K (2024-08-26)
8-K (2024-07-17)
8-K (2024-05-20)
8-K (2024-05-17)
8-K (2024-05-01)
8-K (2024-04-29)
8-K (2024-04-16)
8-K (2024-01-23)
8-K (2023-12-05)
8-K (2023-11-30)
8-K (2023-11-27)
8-K (2023-10-23)
8-K (2023-10-17)
8-K (2023-08-30)
8-K (2023-08-25)
8-K (2023-07-28)
8-K (2023-07-24)
8-K (2023-07-20)
8-K (2023-05-08)
8-K (2023-05-01)
8-K (2023-04-18)
8-K (2023-04-04)
8-K (2023-04-03)
8-K (2023-02-14)
8-K (2023-01-24)
10-Q (2025-04-23)
10-Q (2024-10-23)
10-Q (2024-07-25)
10-Q (2024-05-01)
10-Q (2023-10-27)
10-Q (2023-07-31)
10-Q (2023-04-28)
10-K (2025-02-13)
10-K (2024-02-16)
10-K (2023-02-16)
Earnings Calls
Earnings Report 2025Q1
Earnings Report 2024Q4
Earnings Report 2024Q3
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-10-17)
Factset
Factset Business Description
Factset Street Account
The Janssen Pharmaceutical Companies of Johnson & Johnson announcesTAR-200 intravesical delivery system results show 77% complete response rate in patients with BCG-unresponsive, HR-NMIBC ($153.00, 0.00) (2023-10-22T14:01:16Z)
The Janssen Pharmaceutical Companies of Johnson & Johnson announces TAR-210 shows early evidence of positive clinical activity in patients with non-muscle-Invasive bladder cancer with select fibroblast growth factor receptor alterations ($153.00, 0.00) (2023-10-22T13:57:23Z)
StreetAccount Metrics Recap - Johnson & Johnson Q3 Earnings ($157.53, 0.00) (2023-10-17T10:47:49Z)
StreetAccount Earnings Call Q&A Summary: Johnson & Johnson Q3 ($156.98, -0.55) (2023-10-17T16:06:42Z)
StreetAccount Consensus Metrics Preview - Johnson & Johnson Q3 Earnings ($155.77, -0.41) (2023-10-12T18:10:46Z)
Street Takeaways - Johnson & Johnson Q3 Earnings ($152.80, -3.29) (2023-10-18T16:43:13Z)
Phase 3 MAGNITUDE study shows trend toward improvement in overall survival in patients with mCRPC with BRCA alterations treated with niraparib and abiraterone acetate plus prednisone ($153.00, 0.00) (2023-10-22T13:54:09Z)
Johnson & Johnson's Janssen reports data from new analyses of VOYAGER PAD trial of Xarelto ($147.63, 0.00) (2023-11-14T12:04:07Z)
Johnson & Johnson upgraded to buy from neutral at UBS ($154.66, 0.00) (2023-12-01T08:17:57Z)
Johnson & Johnson reports receive of Civil Investigative Demands from DOJ in connection with offering lenses and equipment used in eye surgery; says impact of conflict in Israel has, so far, been non-material - 10-Q ($145.60, 0.00) (2023-10-27T20:34:38Z)
Johnson & Johnson reports Q3 adjusted EPS $2.66 vs FactSet $2.52 [14 est, $2.40-2.58] ($157.53, 0.00) (2023-10-17T10:24:13Z)
Johnson & Johnson provides additional FY23 guidance and 2024 Considerations - earnings slides ($157.53, 0.00) (2023-10-17T11:16:15Z)
Johnson & Johnson Medtech acquires Laminar, Inc. for $400M; lowers FY23 guidance ($152.11, 0.00) (2023-11-30T13:46:06Z)
Johnson & Johnson initiated outperform at RBC Capital Markets ($155.52, 0.00) (2023-10-05T02:49:17Z)
Johnson & Johnson announces MONARCH Platform for Bronchoscopy receives regulatory license for China ($147.63, 0.00) (2023-11-13T21:56:04Z)
Johnson & Johnson announces departure of worldwide chairman of MedTech Ashley McEvoy; to be succeeded by Tim Schmid ($151.39, 0.00) (2023-10-23T20:31:53Z)
Janssen reports results from the Phase 3 MARIPOSA study showing RYBREVANT in combination with lazertinib compared to osimertinib resulted in a 30% reduction in the risk of disease progression or death ($153.01, +0.01) (2023-10-23T14:37:27Z)
Janssen Pharmaceutical Companies of Johnson & Johnson announced data from the Phase 2a IRIS-RA clinical study for the treatment of adults living with moderate to severe active rheumatoid arthritis (RA) ($151.49, -0.21) (2023-11-07T15:06:18Z)
Janssen notes new data for TREMFYA and JNJ-2113 at the EADV Congress ($157.64, 0.00) (2023-10-09T11:38:49Z)
Janssen announces new data from the CorEvitas Psoriatic Arthritis (PsA) and Spondyloarthritis Registry ($150.90, 0.00) (2023-11-08T14:03:52Z)
Janssen announces new data from QUASAR Phase 3 induction study demonstrating efficacy and safety profile of TREMFYA ($153.00, 0.00) (2023-10-23T11:34:27Z)
Wikipedia
Johnson_&_Johnson